The U.S. Food and Drug Administration has approved Atebrioz (zilurgisertib), a once-daily oral therapy developed by Mirum Pharmaceuticals, for the treatment of fibrodysplasia ossificans progressiva in patients aged 12 years and older. The September 25, 2026 approval marks only the third time an FDA-approved treatment has been available for this devastating ultra-rare condition, in which the body progressively and irreversibly replaces muscle, tendon, and ligament tissue with bone.
What FOP Does to the Body
Fibrodysplasia ossificans progressiva, caused by a specific gain-of-function mutation in the ACVR1 gene encoding a bone morphogenetic protein receptor called ALK2, essentially causes a second skeleton to form outside the normal one. Episodes of painful, inflammatory flares—often triggered by minor trauma, injections, or even viral illness—accelerate the accumulation of heterotopic bone. Over time, joints lock, mobility disappears, and patients lose the ability to open their mouths, raise their arms, or walk. Most patients are wheelchair-dependent before age 30, and the condition significantly shortens life expectancy.
FOP affects roughly one in two million people globally. There is no cure.
How Atebrioz Works
Atebrioz targets the root biological problem directly. Zilurgisertib is a selective inhibitor of ALK2, the kinase receptor that carries the mutation driving FOP. By blocking ALK2 signaling, the drug aims to suppress the downstream cascade that ultimately converts soft tissue into bone, a process called heterotopic ossification. This mechanism distinguishes Atebrioz from palovarotene, a retinoic acid receptor gamma agonist approved as Sohonos, which works through a different pathway, and from garetosmab, an anti-Activin A antibody that has also received approval.
The Clinical Evidence
FDA approval was supported by results from a 63-patient randomized, double-blind, placebo-controlled trial (NCT05090891) followed by a 292-week open-label extension. The primary measure was reduction in heterotopic ossification volume—the amount of abnormal bone that formed or grew during the study period. Patients treated with Atebrioz showed meaningful reduction in HO volume compared to placebo, offering the clearest evidence to date that ALK2 inhibition can slow or reduce the core pathological process of the disease.
Access and Patient Support
Mirum Pharmaceuticals has established the Mirum Access Plus program (MAP) to facilitate patient access ahead of the full commercial launch planned for October 2026. Eligible patients may pay as little as zero dollars out of pocket through this program. Side effects observed in clinical trials included headache, joint pain, upper respiratory tract infections, nosebleeds, and nausea. The prescribing information carries a warning for embryo-fetal toxicity, and women of reproductive potential are advised to use effective contraception during treatment.
Chris Peetz, Chief Executive Officer, Mirum Pharmaceuticals
Rare Disease Priority Review Voucher
The FDA also issued Mirum a Rare Pediatric Disease Priority Review Voucher upon approval. These vouchers can be redeemed to receive priority review for a future drug application or sold on the open market, where they have historically commanded prices in the tens of millions of dollars. The voucher was transferred to Incyte Corporation under a prior agreement, underscoring one of the few financial mechanisms available to incentivize drug development in conditions as rare as FOP.
What Comes Next
Atebrioz currently covers patients 12 years and older. A dedicated clinical program called PROGRESS is underway for younger children aged 2 to less than 12 years. The European Medicines Agency has also begun review of a marketing authorization application for zilurgisertib, meaning patients in Europe may see a regulatory decision in the coming months to years.
For a disease that had no approved treatment until recently, the arrival of three distinct mechanistic approaches in relatively quick succession reflects the degree to which FOP has attracted serious scientific attention since the ACVR1 mutation was identified as a druggable target. The field now has the unusual opportunity to study how different inhibitory strategies applied to the same root pathway may complement or compare against each other in long-term outcomes.